Zelluna ASA - Successful private placement and retail offering

Core Insights - Zelluna ASA has successfully raised NOK 58 million to advance its TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials for treating solid cancers [1][2][4] - The financing was strongly supported by existing shareholders and management, indicating confidence in the potential of Zelluna's TCR-NK platform [3][6] - The company aims to deliver a new generation of allogeneic "off-the-shelf" cell therapies, combining T-cell receptors with natural killer cells to enhance treatment efficacy [4][5] Financial Details - The private placement raised NOK 55 million through the allocation of 5,500,000 shares at NOK 10 per share, with an additional NOK 3.16 million raised from the PrimaryBid Offering [8][9] - The net proceeds will be utilized to initiate the Phase I clinical trial, develop the pipeline, and for general corporate purposes [9] Shareholder Engagement - The financing reflects strong investor confidence, with participation from both existing and new investors, showcasing a commitment to Zelluna's vision and scientific approach [5][6] - A subsequent repair offering of up to 800,000 new shares is planned to mitigate dilution effects for existing shareholders not participating in the private placement [18] Clinical Development - The company is positioned to initiate its first clinical study with the world's first MAGE-A4-targeting TCR-NK therapy, which could significantly impact treatment for solid tumors [4][5] - The successful financing marks a pivotal milestone in Zelluna's journey from innovation to clinical validation, with a focus on scalable "off-the-shelf" cell therapies [4][6]